Dexcom's Q3 2020 results showed significant growth in revenue and operating income compared to the same quarter of the previous year. Revenue increased by 26% to $500.9 million, and GAAP operating income rose to $94.1 million, or 18.8% of revenue. The company also raised its full-year 2020 guidance.
Revenue grew 26% year-over-year to $500.9 million.
U.S. revenue increased by 29%, while international revenue grew by 17%.
GAAP operating income was $94.1 million, representing 18.8% of revenue, a 470 basis point increase from Q3 2019.
The company raised its full-year 2020 revenue guidance to approximately $1.900 billion, representing 29% growth.
The company is updating guidance for fiscal year 2020 revenue, gross profit, operating margin, and Adjusted EBITDA margin as follows:
Visualization of income flow from segment revenue to net income